Literature DB >> 1905720

Independent assembly and secretion of a dimeric adhesive domain of von Willebrand factor containing the glycoprotein Ib-binding site.

H Azuma1, J A Dent, M Sugimoto, Z M Ruggeri, J Ware.   

Abstract

von Willebrand factor (vWF) is a multimeric glycoprotein that supports platelet adhesion on thrombogenic surfaces as part of the normal hemostatic response to vascular injury. We have employed a domain-specific expression strategy to analyze the biosynthetic processing steps and minimum structural requirements for assembly of the platelet receptor glycoprotein Ib-binding domain of vWF. A chimeric cDNA that codes for the vWF signal peptide and a segment of vWF internal primary sequence, residues 441-730, directs the secretion of a functional vWF fragment from mammalian cells. The recombinant molecule intrinsically assembles through intermolecular disulfide bond formation into a dimeric adhesive domain without contributions from other regions of vWF, including propeptide, previously indicated as essential for vWF multimer assembly. Prevention of N-linked glycosylation on the recombinant domain does not impair dimer formation or the ability to support platelet aggregation. These results identify a minimum structural element for vWF subunit assembly and provide new insights into the processing steps to produce vWF multimers and adhesive domains.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905720

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  The linker between the D3 and A1 domains of vWF suppresses A1-GPIbα catch bonds by site-specific binding to the A1 domain.

Authors:  Alexander Tischer; Miguel A Cruz; Matthew Auton
Journal:  Protein Sci       Date:  2013-08       Impact factor: 6.725

2.  Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Authors:  Roberta Donadelli; Jennifer N Orje; Cristina Capoferri; Giuseppe Remuzzi; Zaverio M Ruggeri
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

4.  A discontinuous autoinhibitory module masks the A1 domain of von Willebrand factor.

Authors:  W Deng; Y Wang; S A Druzak; J F Healey; A K Syed; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2017-08-09       Impact factor: 5.824

5.  A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.

Authors:  I Tornai; J Arnout; H Deckmyn; K Peerlinck; J Vermylen
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

6.  ADAP is required for normal alphaIIbbeta3 activation by VWF/GP Ib-IX-V and other agonists.

Authors:  Ana Kasirer-Friede; Barry Moran; Jennifer Nagrampa-Orje; Ken Swanson; Zaverio M Ruggeri; Burkhart Schraven; Benjamin G Neel; Gary Koretzky; Sanford J Shattil
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

7.  von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.

Authors:  L Holmberg; J A Dent; R Schneppenheim; U Budde; J Ware; Z M Ruggeri
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.

Authors:  Angie R Purvis; Julia Gross; Luke T Dang; Ren-Huai Huang; Milan Kapadia; R Reid Townsend; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

Review 9.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

10.  Candida albicans elicits protective allergic responses via platelet mediated T helper 2 and T helper 17 cell polarization.

Authors:  Yifan Wu; Zhimin Zeng; Yubiao Guo; Lizhen Song; Jill E Weatherhead; Xinyan Huang; Yuying Zeng; Lynn Bimler; Cheng-Yen Chang; John M Knight; Christian Valladolid; Hua Sun; Miguel A Cruz; Bernhard Hube; Julian R Naglik; Amber U Luong; Farrah Kheradmand; David B Corry
Journal:  Immunity       Date:  2021-09-09       Impact factor: 31.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.